https://clinicaltrials.gov/ct2/show/NCT04707469
Feb 3rd, 2023 - This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e...
https://clinicaltrials.gov/ct2/show/NCT04460885
Feb 3rd, 2023 - This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. Participants will either get insulin icodec that participants will have to inject ...
https://clinicaltrials.gov/ct2/show/NCT04646473
Feb 3rd, 2023 - ASSIGNMENT OF PARTICIPANTS: Interested participants will download the SweetGoals app. Once all screening procedures are complete, including A1c verification via the mail in test kit, research staff will schedule a web video meeting to (1) randomize participants and inform them of their intervention condition assignment; (2)assist participants in setting up their Glooko account and uploading the...
https://clinicaltrials.gov/ct2/show/NCT04848480
Feb 3rd, 2023 - This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily. Participants will either get insulin icodec that participants will have to inject once a week on the same day of the week, or ...
https://clinicaltrials.gov/ct2/show/NCT04853810
Feb 3rd, 2023 - The use of technological tools in the treatment of diabetes has intensified and become common in recent years. Many of these systems adhere to the skin with an adhesive in place for between 2 and 14 days, or even longer, depending on the system under consideration. Unfortunately, an increase in skin reactions has been observed in diabetic patients using these new technologies, sometimes leading...
https://clinicaltrials.gov/ct2/show/NCT03022682
Feb 3rd, 2023 - The Inflammation, Diabetes, Ethnicity and Obesity (IDEO) cohort is recruiting 350 individuals from various ethnicities, covering a spectrum of weight and Diabetes risk. The study is looking for participants between the ages of 18-75 years that are healthy with or without diabetes with a stable weight. The study will also like to include people who are slated to undergo any type of bariatric sur...
https://clinicaltrials.gov/ct2/show/NCT03734107
Feb 3rd, 2023 - Research Design and Methods Overview of Study Design & Procedure. The aim of this randomized controlled trial (RCT) is to determine the efficacy of a behavioral intervention targeting health communication skills and diabetes self-management skills in preparation for the transfer to adult diabetes care, compared to usual care. The intervention, Plan, Reflect, and Engage with Providers for Diabet...
https://clinicaltrials.gov/ct2/show/NCT02810990
Feb 3rd, 2023 - Bosutinib is a potent tyrosine kinase inhibitor (TKI) active at nM concentration on BCR-ABL1 and most BCR-ABL1 mutations. Bosutinib has been approved by the FDA and the EMA for the treatment of patients with Ph+/BCR-ABL1+ chronic myeloid leukemia who fail treatment with other TKIs, first or second line. The goal of second-line treatment of CML is to achieve a response that would predict for a s...
https://clinicaltrials.gov/ct2/show/NCT04927702
Feb 3rd, 2023 - In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care. In participants with venous leg ulcers (VLUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with living cellular skin substitute (Apligraf®)
https://clinicaltrials.gov/ct2/show/NCT04321395
Feb 3rd, 2023 - Nonalcoholic fatty liver disease (NAFLD) is a common complication of obesity and is associated with an increased risk of developing type 2 diabetes. The hallmark feature of NAFLD is an increase in intrahepatic triglyceride (IHTG) content. Data from studies conducted in rodent models suggest increased IHTG content can alter hepatic vagal afferent nerve (HVAN) activity. In rodent models of obesit...
https://clinicaltrials.gov/ct2/show/NCT04221750
Feb 3rd, 2023 - The growing prevalence of obesity in older adults including many older Veterans, has become a major concern in the US already strained health care system in general and in the VA in particular. In older adults, obesity exacerbates the age-related decline in physical function resulting in frailty, decrease in quality of life, loss of independence, and increase in nursing home admissions. The inv...
https://clinicaltrials.gov/ct2/show/NCT05702931
Feb 3rd, 2023 - Introduction: In renal transplant recipients, hyperglycaemia develops frequently in the immediate period after renal transplantation. Insulin is the primary choice of treatment but carries the adherent risk of hypoglycaemia and weight gain. Tablet semaglutide is a potent glucose-lowering agent that can reduce weight and the incidence of hypoglycaemia. It also has the ability to delay progressio...
https://clinicaltrials.gov/ct2/show/NCT05712720
Feb 3rd, 2023 - Diabetic macular edema (DME) is a common retinal microvascular complication in diabetic patients that can lead to progressive loss of visual acuity and ultimately to complete vision loss. DME is the main cause of vision loss in patients with Type 2 diabetes. There is a significant unmet medical need to develop better therapies of DME and diabetic retinopathy (DR). RZ402 is a potent and selectiv...
https://clinicaltrials.gov/ct2/show/NCT05711602
Feb 3rd, 2023 - This is a randomized clinical trial of single-blind with 2 arms (Control group and experimental group), in which a pre-treatment-postest design has been used. The study will define two groups: A control group (CG) that will not be submitted to treatment, which will be evaluated in the pre and post phase of the study. Participants assigned to this group will receive general advice on the positiv...
https://clinicaltrials.gov/ct2/show/NCT05711355
Feb 3rd, 2023 - Introduction Meningomyelocele (MMC), a form of spina bifida, is the most common congenital anomaly of the central nervous system. It occurs in the first four weeks of pregnancy when the neural tube of the embryo fails to close. Neural tube defects may result in hydrocephalus, hindbrain herniation, and exposure to toxins in the amniotic fluid, with potential morbidity and mortality (1). Both env...
https://clinicaltrials.gov/ct2/show/NCT05580536
Feb 3rd, 2023 - Although the Arab American (AA) population is at a higher risk of pre-diabetes and type 2 diabetes (T2D) compared to the white non-Hispanic population, there are hardly any culturally appropriate diabetes self-management resources available for Arab Americans. Project Dulce Arabic is a pilot study addressing both the linguistic and cultural barriers faced by the AA community in diabetes self-ma...
https://clinicaltrials.gov/ct2/show/NCT05632965
Feb 3rd, 2023 - The most common thyroid function disorder in premature infants is physiological hypothyroxinemia, followed by hypothyroidism of non-thyroidal causes. In pre-maturity, several factors can inhibit the conversion of peripheral T4 to T3, including hypoxemia, acidosis, infections, hypoglycemia, hypocalcemia and malnutrition . Some rare conditions include transient secondary/tertiary hypothyroidism, ...
https://clinicaltrials.gov/ct2/show/NCT05598619
Feb 3rd, 2023 - Recent studies have shown that many vitamins, if consumed in high daily dosages or delivered to the colon, can modulate the gut microbiota and their metabolites. In parallel, gut microbiota imbalances are linked to diseases, e.g., obesity, type 2 diabetes, cardiovascular disease, autoimmune diseases, and intestinal inflammatory diseases. Therefore, vitamin administration could offer health bene...
https://clinicaltrials.gov/ct2/show/NCT05548881
Feb 3rd, 2023 - Study Description: This is a deep phenotype study of women who are determined to have 45,X mosaicism as a secondary genomic finding following cfDNA sequencing during pregnancy. Objectives: To define and describe a comprehensive phenotype of women with confirmed 45,X mosaicism initially found by cfDNA including cardiovascular, skeletal, metabolic, reproductive, audiometric, immunologic, and psyc...
https://clinicaltrials.gov/ct2/show/NCT05221580
Feb 3rd, 2023 - The purpose of this study is to collect information on how Ryzodeg® works in real-world patients. Participants will get Ryzodeg® as prescribed to by their doctor. The study will last for about 5-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment
